On May 21, GSK (GSK) Announces Its Long-Acting IL-5AntibodyDepemokimab Achieves Positive Results in Two Phase III Clinical Trials, SWIFT-1 and SWIFT-2, for the Treatment of Severe Eosinophilic Asthma (SEA) in Adults and Adolescents, Significantly Reducing Asthma Exacerbation Frequency Over 52 Weeks.
DepemokimabIt is the first ultra-long-acting biologic to be evaluated in a Phase III trial, demonstrating high affinity and potency for interleukin-5 (IL-5) and requiring administration only once every six months. IL-5 is a key cytokine (protein) in type 2 inflammation. This inflammatory pathology is characterized by elevated blood eosinophil counts, which are responsible for over 80% of severe asthma patients.The potential pathological factors, which can lead to unpredictable deterioration of the condition.GSK previously had an IL-5 monoclonal antibody.MepolizumabIt was first approved for marketing in the United States in November 2015 as an add-on maintenance treatment regimen for SEA patients aged 12 years and above. Currently, Mepolizumab has been approved globally for multiple indications, including: 1) SEA; 2) Bronchial Asthma; 3) Chronic Rhinosinusitis with Nasal Polyps; 4) Chronic Eosinophilic Leukemia/Hypereosinophilic Syndrome; 5) Allergic Granulomatous Vasculitis.This timeThe success of two Phase III studies on Depemokimab will further enhance GSK's leading position in the respiratory field.Copyright © 2024 PHARMCUBE. All Rights Reserved.Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
